ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

CAB Reluctantly Approves Use Of Contract To Support Cancer Journals

February 15, 1985

NCCS Networker Volume 9 Issue 1, Spring 1995

April 13, 1995

Seven New Initiatives For NIH Common Fund

February 26, 2010

DCE Board Demands Other Agencies Pay For NCI AIDS Support Contract, Okays Two RFA Concepts, One Program Announcement, Contract Recompetitions

May 24, 1985

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

Mammography Had Limited Impact Among Swedish Women Age 40-69

July 27, 2012